← Back to Search

Behavioral Intervention

Cognitive Behavioral Therapy for Alcoholism and Cannabis Abuse

Led By Matthew Sloan, MD
Research Sponsored by Centre for Addiction and Mental Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights


This trial aims to understand how to tailor treatments for alcohol & cannabis use disorder, by assessing how 3 neurofunctional domains affect response to therapy.

Who is the study for?
This trial is for adults over 18 who have been diagnosed with alcohol use disorder (AUD) or cannabis use disorder (CUD), are willing to participate in group therapy, and can abstain from substances before assessments. They must meet specific criteria for risky drinking or frequent cannabis use. Those unable to communicate in English or unwilling to follow the study's abstinence requirements cannot join.Check my eligibility
What is being tested?
The study tests if assessing three brain functions—executive function, incentive salience, and negative emotionality—before treatment can predict how well people with AUD or CUD respond to therapy. Participants will receive 12 weeks of cognitive behavioral therapy (CBT), with additional pharmacotherapy for AUD if needed.See study design
What are the potential side effects?
Since this trial involves cognitive behavioral therapy and motivational enhancement therapy, there may not be direct side effects like those seen with medications; however, participants might experience emotional discomfort discussing substance use.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Amount of Cannabis Used Per Week (grams/week) During Treatment Assessed by the Timeline Followback Interview (TLFB) (CUD group)
Change in Average Drinks Per Day During Treatment Assessed by the Timeline Followback Interview (TLFB) (AUD Group)
Change in Cannabis Use Frequency During Treatment Assessed by the Timeline Followback Interview (TLFB) (CUD group)
+3 more
Secondary outcome measures
Change in Anxiety Symptoms During Treatment Using the Generalized Anxiety Disorder-7 (GAD-7) (AUD and CUD groups)
Change in Depressive Symptoms during Treatment Assessed Using the Patient Health Questionnaire-9 (PHQ-9) (AUD and CUD groups)
Change in Quality of Life During Treatment Assessed Using the Abbreviated World Health Organization Quality of Life Scale (WHOQOL-BREF) (AUD and CUD Groups)
+1 more

Side effects data

From 2009 Phase 2 & 3 trial • 162 Patients • NCT00248612
suicidal ideation
Study treatment Arm
Venlafaxine & PMR
Venlafaxine & CBT
Placebo & CBT
Placebo & PMR

Trial Design

2Treatment groups
Experimental Treatment
Group I: Cannabis Use DisorderExperimental Treatment1 Intervention
Participants will be treated with 12 weeks of CBT + motivational enhancement therapy for CUD (group therapy).
Group II: Alcohol Use DisorderExperimental Treatment1 Intervention
Participants will be treated with 12 weeks of CBT for AUD (group therapy) and have the option to receive evidence-based pharmacotherapy for AUD guided by a pharmacotherapy algorithm.
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3

Find a Location

Who is running the clinical trial?

Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of OntarioUNKNOWN
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,354 Previous Clinical Trials
26,460,119 Total Patients Enrolled
5 Trials studying Alcoholism
443 Patients Enrolled for Alcoholism
Centre for Addiction and Mental HealthLead Sponsor
359 Previous Clinical Trials
81,159 Total Patients Enrolled
17 Trials studying Alcoholism
3,135 Patients Enrolled for Alcoholism

Media Library

CBT (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05855668 — N/A
Alcoholism Research Study Groups: Cannabis Use Disorder, Alcohol Use Disorder
Alcoholism Clinical Trial 2023: CBT Highlights & Side Effects. Trial Name: NCT05855668 — N/A
CBT (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05855668 — N/A
~267 spots leftby Dec 2027